Glenmark Pharma, Mylan to sell generic version of anti-malarial drug in UK: Report

20 Mar 2013 Evaluate

Glenmark Pharmaceuticals along with Mylan is reportedly planning to sell the generic versions of the drug Malarone, most successful anti-malarial medication in the UK. With UK court withdrawing GlaxoSmithKline’s patent on the drug, Glenmark Generics was able to launch the first generic version of the drug, Atovaquone proguanil, in the UK in early February.

This development came after Glenmark’s subsidiary, Glenmark Generics (Europe) and Mylan filed a case against The Welcome Foundation and Glaxo Group, for revocation of Glaxo’s patent for its anti-malarial product, Malarone.

Meanwhile, Atovaquone proguanil, which is the generic version of Malarone, is indicated for acute, uncomplicated falciparum malaria. Based on IMS Health sales data for the 12-month period ending September 2012, the drug had garnered sales of Euro 20.69 million in the UK.

GlaxoSmithKline, back in 2009, had filed a patent infringement lawsuit against Glenmark after the USFDA allowed the latter to market a generic version of the malaria drug. However, in April 2010, Glenmark settled the patent litigation with GlaxoSmithKline and was allowed to sell the generic tablets under a royalty bearing licence from GlaxoSmithKline in the third quarter of 2011, or earlier under certain circumstances.

Glenmark Pharma Share Price

1919.05 -46.70 (-2.38%)
08-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1795.30
Dr. Reddys Lab 1267.15
Cipla 1497.45
Zydus Lifesciences 924.35
Lupin 2071.35
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×